Markus Warmuth, Monte Rosa Therapeutics CEO
October 28, 2024 07:00 AM EDT
Deals

No­var­tis pays Monte Rosa $150M for Phase 1 drug in lat­est en­dorse­ment of mol­e­c­u­lar glues

Max Bayer

Pharma Reporter

No­var­tis is get­ting a hold of one of Monte Rosa Ther­a­peu­tics’ clin­i­cal-stage mol­e­c­u­lar glues, and it’s putting more than $2.2 bil­lion on the ta­ble. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times